CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
in children and adolescents with newly diagnosed chronic myeloid leukemia (CML), or in children with Ph+ acute lymphoblastic leukemia...
Phase 2
Birmingham, Alabama, United States and 173 other locations
single-agent in the setting of Relapsed or refractory acute myeloid leukemia (R/R AML).The dose escalation (Part A) of the study will explor...
Phase 1
Birmingham, Alabama, United States and 13 other locations
in future studies in study participants diagnosed with acute myeloid leukemia (AML), myelodysplastic syndromes with increased blasts grade 2...
Phase 1, Phase 2
Birmingham, Alabama, United States and 33 other locations
GDX012 is a novel cell therapy developed for the treatment of certain types of cancer, including Acute Myeloid Leukemia (AML). The main aims...
Phase 1, Phase 2
Birmingham, Alabama, United States and 13 other locations
chemotherapy regimen for the treatment of B-cell acute lymphoblastic leukemia. Part 1 of the study will optimize the dose of study drug (rux...
Phase 2
Birmingham, Alabama, United States and 110 other locations
phase I study to determine the maximum tolerated dose of adding Loncastuximab Tesirine to Aclabrutinib in the treatment of chronic lymphocytic leukemia...
Phase 1
Birmingham, Alabama, United States
with FMS-like tyrosine kinase (FLT3) mutated acute myeloid leukemia (AML) who are refractory to or have relapsed after first-line AML therap...
Phase 3
Birmingham, Alabama, United States and 125 other locations
safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of DR-01 in adult patients with large granular lymphocytic leukemia...
Phase 1, Phase 2
Birmingham, Alabama, United States and 33 other locations
This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, for the treatment of patients with Ph+ Chronic Myeloid Leukemia...
Phase 1, Phase 2
Birmingham, Alabama, United States and 25 other locations
The purpose of this study is to determine the recommended Phase 2 dose (RP2D) candidate(s) of bleximenib in combination with AML directed therapies (...
Phase 1
Birmingham, Alabama, United States and 30 other locations
Clinical trials
Research sites
Resources
Legal